

RNS Number : 8819G  
EKF Diagnostics Holdings PLC  
20 March 2020

**EKF Diagnostics Holdings plc**  
("EKF", the "Company")

**Investor results briefing update**

As stated on the 4 March 2020, EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.

A briefing open to all investors was meant to take place on Tuesday 24 March 2020. The decision has been made by the management team to cancel this event. Instead the results presentation will be made available on the Company's website to download here:  
<https://www.ekfdiagnostics.com/documents-reports.html>

If you have any questions, please contact the team at Walbrook PR on 0207 933 8780 or at [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com).

**EKF Diagnostics Holdings plc**  
Christopher Mills, Non-Executive Chairman  
Julian Baines, CEO  
Richard Evans, FD & COO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
**Tel: 029 2071 0570**

**N+1 Singer (Nomad & Broker)**  
Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate Finance)  
Tom Salvesen (Corporate Broking)

**Tel: 020 7496 3000**

**Walbrook PR Limited**  
or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)  
Paul McManus/ Lianne Cawthorne

**Tel: 020 7933 8780**  
Mob: 07980 541 893 / 07584 391  
303

**About EKF Diagnostics Holdings plc ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))**

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

NRAKKBDOBKDON admin Investor results briefing update 30417865 A Fri, 03/20/2020 - 07:00  
LSE RNS Company Announcement - General EKF